anmelden
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
Werte in diesem Artikel
ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.
23rd Annual Needham Virtual Healthcare Conference
Presentation Time | Thursday, April 11 at 10:15 a.m. EST |
Presenters | Raj Kannan, CEO; John Hayslip CMO |
Webcast link | |
Meetings | One-on-one and small group meetings: April 11, 2024 |
Management | Raj Kannan, CEO Joe Skelton, CFO John Hayslip, CMO |
The webcast will also be available under "Event Calendar" on I-Mab's IR website
at http://ir.i-mabbiopharma.com/
For more information, please contact your Needham representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and in San Diego, California. For more information, please visit http://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-23rd-annual-needham-virtual-healthcare-conference-302108935.html
SOURCE I-Mab Biopharma
Ausgewählte Hebelprodukte auf I-MAB (spons. ADRs)
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf I-MAB (spons. ADRs)
Der Hebel muss zwischen 2 und 20 liegen
